
28.53 Delayed Data As of Apr 16 | ![]() Today’s Change | 12.30 Today|||52-Week Range 29.65 | +88.57% Year-to-Date |
The 7 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 35.00, with a high estimate of 47.00 and a low estimate of 21.00. The median estimate represents a +22.68% increase from the last price of 28.53.
The current consensus among 7 polled investment analysts is to Buy stock in Cara Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.